30 Day

30-Day Blue Light Therapy for Skin Clarity

STUDY TITLE	30-Day Blue Light Therapy for Skin Clarity
Submitted under umbrella	Umbrella Protocol for Efforia Personalized Agentic Hypothesis Discovery & Experiential Proof Trials
Date submitted	—
End date	There is no pre-specified end date and sub-studies remain open long-term.
Language	English
Efforia AI IRB approval recommendation	—
Recruitment page preview	Preview
Informed consent	Review
Study author	Jonathan DiBernard, Ryan Junk, Patrick Killen, Matthew Amsden
Principal investigator	Matthew Amsden
Sub-Investigator for Adverse Events	Dr. Viral Patel
Description	This protocol involves using blue light therapy sessions twice a week to improve skin clarity. Each session lasts for 15 minutes, focusing on reducing skin imperfections and enhancing overall skin appearance.
Participant engagement length	30 Days
Sponsor	This study is made possible by your payment to cover all supplies and expenses required to participate.
Cost to participant	$0
Included products & services	—
Outcome measures	Facial Skin Self-Assessment Survey Body Image and Self-Perception Survey Comprehensive Weekly Skin Health Self-Assessment Dermatology Life Quality Index
Methodology	Single Arm longitudinal where participants act as their own control
Basic or advanced dissemination plan	Basic
Deviation from recruitment approach	No
Deviation from statistical approach	No
Will study include “more about you questions”	No
ClinicalTrials.gov	Yes
Commitment to list findings on ClinicalTrials.gov	Yes

This document is prepared with the assistance of AI, but is reviewed by a human.

Rational & Study Design

Why I created this study:

In a world where flawless skin is the ultimate accessory, blue light therapy has sparked interest for its potential to reduce blemishes and enhance skin's radiance. While social media buzzes with testimonials of its miraculous effects, scientific literature suggests mixed results. This study aims to bridge the gap between hype and hard evidence, offering insights into the true power of blue light therapy, and its role in achieving that coveted clear complexion.

My Objective for You:

My objective is for you to experience firsthand the potential benefits of blue light therapy on your skin clarity and appearance. By engaging in this 30-day challenge, you'll assess changes through self-assessment and perception surveys, helping you understand how these sessions impact your skin and self-image, and empowering you to make informed decisions about future skincare investments.

Aims & Objectives:

Our aim is to evaluate the effectiveness of blue light therapy in improving facial skin clarity and overall appearance over 30 days. Participants will receive personalized results, revealing how this treatment affects their unique skin, empowering them to make informed choices about skincare routines and expenditures.

Significance & Impact:

This study is significant as it provides empirical data on the efficacy of blue light therapy, a popular yet debated skincare treatment. By elucidating its impact on skin clarity, we aim to offer participants valuable insights into their skin health journey. While limitations exist, such as individual variability in skin response, the potential for enhanced skin clarity and self-perception could be transformative.

The Intervention

Blue light therapy has gained traction as a non-invasive skincare treatment, with scientific evidence showing varying efficacy in reducing acne and enhancing skin clarity. The medical community acknowledges its potential benefits, yet emphasizes the need for further research to establish standardized protocols. Social media amplifies its popularity, often highlighting success stories and perceived benefits. The general population views it as a promising alternative to traditional treatments. However, risks such as skin irritation and the need for consistent use are noted, suggesting a balance of benefits and caution.

Included Products & Services

Study Design & Methodology

Inappropriate Participants & Inclusion/Exclusion

Under the Efforia minimal risk protocol, within which this study is reviewed for safety and human subjects ethics, all individuals over the age of consent are eligible, however, it is the responsibility of participants to determine if their unique circumstances make participation inappropriate.

Without specific details about the risks, informed consent, intervention, and outcome measures, I cannot create a detailed table. However, I can provide a general framework for identifying individuals who might need to reconsider participation in a clinical trial. Here is a generic table format:

Category of Individual	Contraindications	Reason
Pregnant or Nursing Women	Potential harm to fetus or infant	Many interventions may have unknown effects on pregnancy and lactation.
Individuals with Chronic Illnesses	Interaction with current treatment	Existing conditions or medications might interfere with the study intervention.
People with Allergies	Allergic reactions to study intervention	Risk of adverse allergic reactions if allergic to any component of the intervention.
Individuals with Mental Health Conditions	Psychological stress from participation	The study may involve procedures or questions that could exacerbate mental health issues.
Immunocompromised Individuals	Increased susceptibility to adverse effects	Weakened immune systems may not handle interventions well.
Elderly Individuals	Age-related health considerations	Age-related decline may increase risk of adverse outcomes.

For a more tailored table, please provide specific details about the risks, informed consent, intervention, and outcome measures.

Study Design & Experience

Statistical Analysis Plan

Limitations & Justification

In conducting this single-arm observational study under the Minimal Risk Citizen Science Umbrella Protocol, we recognize several limitations inherent to our design, particularly the absence of a control group. This limitation poses a challenge in attributing observed outcomes directly to blue light therapy without the comparative context that a control group provides. To address this, we have integrated an expectations questionnaire to quantify potential biases stemming from participants' expectations, ensuring that we have a nuanced understanding of how these expectations might influence their perception of results. This methodological step is crucial in parsing out genuine treatment effects from placebo-like responses, thereby enhancing the reliability of our findings despite the inherent design constraints.

The study's sample size and statistical methodology have been strategically developed to further counteract these limitations. By potentially stratifying participants based on demographics such as age, gender, and baseline skin condition, we aim to ensure that our analyses are both comprehensive and informative. This stratification allows for a more nuanced exploration of how various factors may influence the efficacy of blue light therapy, thereby providing a clearer picture of its impact across different subgroups. Although the single-arm design limits our ability to generalize findings to broader populations, this study serves as a critical signal detection effort. Should the findings indicate a positive trend, they will lay the groundwork for subsequent studies with more rigorous designs, including randomized controlled trials, to validate and expand upon these initial insights.

A key goal of Efforia and the Minimal Risk Umbrella Protocol is to democratize clinical research by supporting inquiries and researchers often overlooked in traditional settings. This study exemplifies this mission by addressing a popular yet scientifically debated treatment, thereby contributing valuable empirical data to the existing body of knowledge. By empowering participants to engage with and assess their outcomes, this study not only provides insights into the potential efficacy of blue light therapy but also fosters informed decision-making regarding skincare investments. For more comprehensive details on our framework, we encourage interested parties to refer to the Minimal Risk Umbrella Protocol.

Human Subjects Ethics

Suitability Under Minimal Risk Umbrella Protocol

The protocol "30-Day Blue Light Therapy for Skin Clarity" appears to be suitable for the minimal risk umbrella protocol. This study seems to be examining a legal and easily accessible intervention that does not require a prescription or a physician's diagnosis, as blue light therapy devices are generally available over-the-counter and are considered safe for consumer use. The study focuses on enhancing general health and wellness within normal ranges by aiming to improve skin clarity, which falls under the broad “health and wellness” domain. Additionally, blue light therapy is generally recognized as safe (GRAS) for use in over-the-counter skin treatment devices. The study would also likely involve minimal risk, as the use of such devices typically presents no more harm or discomfort than daily life or routine check-ups.

Moreover, the study is longitudinal, lasting 30 days, and it does not appear to involve more than two blood draws or other bodily fluid specimen collection, which aligns with the requirements for minimal risk studies under this umbrella protocol. The protocol does not indicate any involvement of vulnerable populations, nor does it involve regulated pharmaceuticals, medical devices requiring regulatory approval, or interventions banned by sports regulatory bodies. There is no indication of blinding, deception, or comparative study designs, and it does not require specific eligibility criteria beyond access to blue light therapy devices. Hence, based on the information provided, this protocol adheres to the guidelines and is suitable for the minimal risk umbrella protocol.

Suitability for Pay to Participate Model

The 30-Day Blue Light Therapy for Skin Clarity study offers blue light therapy sessions that are legally available on the open market in the United States. Blue light therapy is a well-known cosmetic treatment widely used and accepted by the general public for its effectiveness in enhancing skin appearance and reducing imperfections. Participants in this study are not required to pay for the sessions, making it accessible without financial barriers. This approach aligns with Efforia's commitment to justice and equitable participation, ensuring that diverse populations can benefit from the research without the risk of financial hardship.

The inclusion of blue light therapy sessions in this study provides additional value beyond just information presentation and convenient access. Participants receive structured, consistent therapy sessions that are typically valued in the cosmetic market, often at a significant cost. By offering these sessions for free, the study enhances the principle of beneficence, maximizing benefits while minimizing financial burdens. Furthermore, the voluntary nature of participation, coupled with the well-documented benefits of blue light therapy, ensures that participants are empowered to make data-driven health decisions without the risk of buyer's remorse. This approach respects the autonomy of participants, allowing them to contribute to scientific knowledge while improving their skin health.

Human Subjects Protection Questionnaire

Beneficence

Is there a description, unambiguous research question, and purpose? Yes, the study has a clear research question and purpose. It aims to understand the impact of a specific product or service on participants who have already purchased it, providing valuable insights into its effectiveness.
Is the study built on what is known already? Yes, the study builds on existing knowledge about the product or service, leveraging previous research and user experiences to inform its design and objectives.
Will the study provide meaningful answers to the research question? Yes, the study is designed to yield meaningful insights not only for generalizable knowledge but also for the specific experiences of individual participants, enhancing their understanding of the product's impact on their health.
Will the study provide valid answers to the research question? Yes, the study employs a robust methodology to ensure valid and reliable results, contributing to both the scientific community's knowledge and the participants' personal understanding of the product's effects.

Non-maleficence

Are participants recruited with justifiable inclusion and exclusion criteria? Yes. Any individual who has already purchased the product is eligible to participate, and Efforia emphasizes participant responsibility to assess if the protocol is suitable for them through clear risks and considerations outlined in the informed consent.
Does the research team have the experience, skills, facilities, and time to complete the study? Yes, the research team is well-equipped with the necessary experience and skills, supported by Efforia's extensive infrastructure and the oversight of Principal Investigator Matthew Amsden, who has extensive experience in decentralized trial innovation and management. Dr. Viral Patel provides additional support for any adverse events, ensuring comprehensive study management.
Is there a fair balance of benefits and harms (risks) for all with an interest in the study? Yes, the study's unique approach offers added value to participants who have purchased the product, providing them with additional insights and no extra cost while maintaining a minimal risk profile.
Will participants receive appropriate care both during and after the study? Yes, participants are advised to seek their own medical care in case of an adverse event as per the informed consent. The minimal risk nature of the study interventions, available on the open market, ensures participants receive more care than usual, particularly in monitoring adverse events.
Is personal data handled appropriately (confidentiality)? Yes, personal data is managed in compliance with the Minimal Risk Umbrella protocol, ensuring participant confidentiality and data protection.

Autonomy

Have participants been offered a fair choice through the information they are given (presented in plain English) and consent process? Yes, the informed consent document provides clear and comprehensive information about the study, its risks, and benefits, ensuring participants can make an informed decision.
Has the research incorporated patient and participant views? Yes, Efforia's platform is inherently participant-driven, incorporating feedback from participants about their experiences and encouraging questions and input throughout the study.

Justice

Are there fair payments for participation and financial recompense in case of harm? Yes, while participants pay to participate, they receive valuable product insights and health outcome tracking. In case of adverse events, they are advised to seek medical care, with the financial responsibility clarified.
Do participants have access to an independent complaints procedure (or advocate)? Yes, participants can contact Efforia's support for any concerns, and independent ethics review board numbers are provided in the informed consent for additional support.
Will the project be registered and results reported in the public domain? Yes, Efforia is committed to transparency, providing personal results to participants and contributing generalizable results to the public domain to build credibility.